Anti-LAG-3 binding proteins

1. An antigen binding protein which is capable of binding Lymphocyte Activation Gene 3 (LAG-3) and which comprises CDRL1, CDRL2 and CDRL3 from SEQ ID NO:5 and CDRH1, CDRH2 and CDRH3 from SEQ ID NO:10.

2. The antigen binding protein according to claim 1 , wherein the antigen binding protein is capable of binding LAG-3 expressed on activated T-cells.

3. The antigen binding protein according to claim 1 , wherein the antigen binding protein comprises a human IgG1 constant region and is capable of depleting LAG-3+ activated human T-cells.

4. The antigen binding protein according to claim 1 , wherein the antigen binding protein is a humanised antibody.

5. The humanised antibody according to claim 4 , wherein the humanised antibody comprises a human IgG1 constant region.

6. The humanised antibody according to claim 5 , which is non-fucosylated.

7. A humanised antibody comprising the variable light chain (VL) of SEQ ID NO:4 and the variable heavy chain (VH) of SEQ ID NO:9, wherein the antibody does not comprise fucose on the core carbohydrate structure attached to Asn297.

8. An antigen binding protein as produced by a host cell that comprises an expression vector that comprises a nucleic acid molecule which encodes an antigen binding protein of claim 1 .

9. A method of producing an antigen binding protein, comprising a) culturing a host cell that comprises an expression vector that comprises a nucleic acid molecule which encodes an antigen binding protein of claim 1 under conditions suitable to express the antigen binding protein and b) isolating the antigen binding protein.

10. A pharmaceutical composition comprising a) an antigen binding protein according to claim 1 , and b) a pharmaceutically acceptable carrier.

11. The antigen binding protein of claim 8 , wherein the FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the host cell.